about
Validation of network communicability metrics for the analysis of brain structural networks.Alterations of white matter integrity related to the season of birth in schizophrenia: a DTI study.Microstructure and Cerebral Blood Flow within White Matter of the Human Brain: A TBSS Analysis.General Practitioners' Attitudes towards Essential Competencies in End-of-Life Care: A Cross-Sectional Survey.Linking brain connectivity across different time scales with electroencephalogram, functional magnetic resonance imaging, and diffusion tensor imagingCerebral white matter structure is associated with DSM-5 schizophrenia symptom dimensions.A spontaneous deletion of α-synuclein is associated with an increase in CB1 mRNA transcript and receptor expression in the hippocampus and amygdala: effects on alcohol consumption.Abstracts of Presentations at the International Conference on Basic and Clinical Multimodal Imaging (BaCI), a Joint Conference of the International Society for Neuroimaging in Psychiatry (ISNIP), the International Society for Functional Source ImagiRepeatability analysis of global and local metrics of brain structural networks.Formal thought disorder is related to aberrations in language-related white matter tracts in patients with schizophreniaReasons for and Frequency of End-of-Life Hospital Admissions: General Practitioners' Perspective on Reducing End-of-Life Hospital ReferralsWhite matter correlates of the disorganized speech dimension in schizophreniaGeneral practitioners' attitudes towards early diagnosis of dementia: a cross-sectional surveyDifferentiation of functional gastrointestinal disorders from healthy volunteers by lactulose hydrogen breath test and test mealEarly diagnosis and management of dementia in general practice - how do Swiss GPs meet the challenge?Cardiovascular risk stratification in primary care patients with arterial hypertension: Results from the Swiss Hypertension Cohort Study (HccH)Systematic De-escalation of Successful Triple Antiretroviral Therapy to Dual Therapy with Dolutegravir plus Emtricitabine or Lamivudine in Swiss HIV-positive Persons
P50
Q34790395-EBE68D50-70F5-466E-8C5B-6DAD8A5AF296Q35005684-66B55480-9963-4C7C-9E1A-FFFF27CBA79CQ35945938-B38CC8CB-86FA-4C53-8AA8-C7419DACAF2AQ36266357-2287A54F-14B1-4EB3-88D3-0D249DBD3335Q36752554-596956F1-1E00-4487-B116-208B288C870EQ37049223-1B55EFB6-6980-45BF-8CB9-440C5F991022Q37597181-29AD8F96-81DF-423C-BED3-8D745DEB2C31Q47223408-457081EF-1C1D-4C40-AEB4-C966A7B43294Q51107631-D1F823DC-DDDF-4833-9187-D1347B8313D0Q57502131-5FC025AF-D6F4-4850-8161-1092A5E3301DQ57502140-5FDCF6DF-7776-4F56-8AD4-4E0D4F1430B0Q57502150-F16BBE6F-A2C5-4FE0-B6FD-24F3FFB10495Q64270372-4835356A-C469-476D-B5E1-E85836EE5FFEQ90617047-51A63009-4B99-4528-8AB3-C42A492C5F28Q90700841-83EA7DCB-F6AB-47BD-BE32-A4D7C1FFD909Q92687625-35D033CC-D2C8-4465-B69E-81EAB2AD145BQ92712867-8CCF9A63-3D8E-4FE3-857D-4F966D65D71A
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Stephanie Giezendanner
@ast
Stephanie Giezendanner
@en
Stephanie Giezendanner
@es
Stephanie Giezendanner
@nl
type
label
Stephanie Giezendanner
@ast
Stephanie Giezendanner
@en
Stephanie Giezendanner
@es
Stephanie Giezendanner
@nl
prefLabel
Stephanie Giezendanner
@ast
Stephanie Giezendanner
@en
Stephanie Giezendanner
@es
Stephanie Giezendanner
@nl
P106
P31
P496
0000-0001-5660-9446